Arnold I. Chin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arnold I. Chin has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Matteo Pellegrini
Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, USA
66 shared publications - Ann Ly
Department of Urology, University of California, Los Angeles, California. 1
64 shared publications - Emily Chou
Department of Medicine, University of California Irvine Medical Center, Orange, California, USA
64 shared publications - Hanwei Zhang
Department of Urology, University of California, Los Angeles, California. 1
64 shared publications - Kris Prado
Department of Urology, Stanford University, Stanford, USA
64 shared publications - Liang Wang
Department of Pharmacology and Toxicology, Department of Urology, Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, USA
64 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy
Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an allogeneic stem cell-derived invariant natural killer T (NKT) cell platform engineered to express a high-affinity non-cleavable CD16 receptor (CD16HSC-NKT) for broad enhancement of mAb-based immunotherapy. Using a clinically guided differentiation platform, we generated highly pure and scalable CD16HSC-NKT cells exhibiting robust expression of NK receptors, potent cytotoxic machinery, and a Th1-biased cytokine profile. CD16HSC-NKT cells demonstrated potent intrinsic antitumor activity and potently enhanced the efficacy of multiple therapeutic antibodies, including Trastuzumab, Tafasitamab, Rituximab, Daratumumab, and Cusatuzumab, across diverse hematologic and solid tumor models. In vivo, combination therapy induced durable tumor eradication and prolonged survival in xenograft models, outperforming the clinically approved antibody-drug conjugate trastuzumab deruxtecan. Mechanistically, therapeutic antibodies promoted the expansion, persistence, and activation of CD16HSC-NKT cells within tumors. CD16HSC-NKT uniquely remodeled the TME by selectively depleting CD1d-expressing tumor-associated macrophages and myeloid-derived suppressor cells. CD16HSC-NKT cells also exhibited minimal alloreactivity, no graft-versus-host disease, and no detectable systemic toxicity. Collectively, these findings establish CD16HSC-NKT cells as a safe, off-the-shelf cellular platform capable of broadly enhancing monoclonal antibody therapy through sustained ADCC, multimodal tumor targeting, and TME remodeling.
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Open AccessEngineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy
Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an allogeneic stem cell-derived invariant natural killer T (NKT) cell platform engineered to express a high-affinity non-cleavable CD16 receptor (CD16HSC-NKT) for broad enhancement of mAb-based immunotherapy. Using a clinically guided differentiation platform, we generated highly pure and scalable CD16HSC-NKT cells exhibiting robust expression of NK receptors, potent cytotoxic machinery, and a Th1-biased cytokine profile. CD16HSC-NKT cells demonstrated potent intrinsic antitumor activity and potently enhanced the efficacy of multiple therapeutic antibodies, including Trastuzumab, Tafasitamab, Rituximab, Daratumumab, and Cusatuzumab, across diverse hematologic and solid tumor models. In vivo, combination therapy induced durable tumor eradication and prolonged survival in xenograft models, outperforming the clinically approved antibody-drug conjugate trastuzumab deruxtecan. Mechanistically, therapeutic antibodies promoted the expansion, persistence, and activation of CD16HSC-NKT cells within tumors. CD16HSC-NKT uniquely remodeled the TME by selectively depleting CD1d-expressing tumor-associated macrophages and myeloid-derived suppressor cells. CD16HSC-NKT cells also exhibited minimal alloreactivity, no graft-versus-host disease, and no detectable systemic toxicity. Collectively, these findings establish CD16HSC-NKT cells as a safe, off-the-shelf cellular platform capable of broadly enhancing monoclonal antibody therapy through sustained ADCC, multimodal tumor targeting, and TME remodeling.
- Open Access
- 29 August 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6  (9) , 102321
Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells
- 29 August 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6  (9) , 102321
Open AccessMultimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells
- Open Access
- 12 November 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5  (11) , 101824
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers
- 12 November 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5  (11) , 101824
Open AccessPD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FDRs and p-values of IFNgamma induced genes
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FDRs and p-values of IFNgamma induced genes
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Normalized gene expression of RNA sequencing
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Normalized gene expression of RNA sequencing
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Exposure times of antibodies used for immunofluorescence
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FOXP3 antibodies not sufficient for ChIP Sequencing
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
FOXP3 antibodies not sufficient for ChIP Sequencing
- Open Access
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Minimal activation of PD-L1 by IL-4 and IL-10 compared to IFNgamma in HT1376 cells
- 25 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition
Minimal activation of PD-L1 by IL-4 and IL-10 compared to IFNgamma in HT1376 cells